Moderna researching booster to tackle COVID-19 variants

Article

Moderna has announced further research into whether a booster shot could provide additional protection with new COVID-19 variants.

The recent discovery of variants of coronavirus disease 2019 (COVID-19) has led to questions about whether the 2 vaccines given emergency use authorization will be effective against them. In vitro neutralization studies run by Moderna show that the vaccine showed activity against both B.1.1.7, the variant first seen in the United Kingdom, and B.1.351, the variant first seen in South Africa.

Although Moderna does expect the vaccine to be able to work with other emerging COVID-19 strains, the company has said that they will study the impact of an additional booster dose. In addition they have begun preclinical studies of a booster candidate specifically targeted at the B.1.351 variant.

In the press release for the news, Stéphane Bancel, CEO of Moderna said, “As we seek to defeat the COVID-19 virus, which has created a worldwide pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforce our confidence that the Moderna COVID-19 vaccine should be protective against these newly detected variants.”

For more on the research, check out our sister publication Medical Economics.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
Tina Tan, MD, comments on FDA expanded approval for MenQuadfi meningococcal disease vaccine
Tina Tan, MD, discusses impact of FDA's stricter COVID-19 vaccine policy for children
Related Content
© 2025 MJH Life Sciences

All rights reserved.